BeOne presents phase 3 data showing BRUKINSA benefits in elderly CLL patients

June 11, 2026 7:24 AM

BeOne Medicines Ltd. (NASDAQ: ONC) presented phase 3 clinical trial data at the 2026 European Hematology Association Congress showing sustained ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found